Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.
This lecture by Derek Connolly was part of an accredited symposium "Redefining intensive LDL-c management in high CV risk patients The case for combination therapy" held during the virtual ESC Congress 2021.
Derek Connolly, MD, PhD is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham, UK.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by unrestricted educational grants received from Amgen, Sanofi, Novartis and Daiichi Sankyo.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Redefining intensive LDL-c management in high CV risk patients - The case for combination therapyExpanding therapeutic options for LDL-c lowering
Prof. Christie Ballantyne, MD
- Redefining intensive LDL-c management in high CV risk patients - The case for combination therapyChanging the paradigm on LDL-c-lowering in high CV risk patients
Prof Kausik Ray